Molecular Pathology and Epidemiology -- Spectrum of Human Pancreatic Neoplasia -- Molecular Genetics of Pancreatic Cancer -- Pancreatic Intraepithelial Neoplasia -- Pathology and Molecular Biology of Intraductal Papillary Mucinous Neoplasms -- Familial Pancreatic Cancer -- Hereditary Pancreatitis and Pancreatic Cancer -- Pancreatic Cancer Biology -- Pancreatic Progenitor Cells in Injury and Regeneration -- Development of the Endocrine and Exocrine Pancreas -- Models of Pancreatic Cancer: Understanding Disease Progression -- From Inception to Invasion: Modeling Pathways to Pancreatic Cancer -- Molecular Signaling Pathways in Pancreatic Cancer -- Pancreatic Cancer Genomics, Epigenomics, and Proteomics -- Pancreatic Cancer Staging -- Imaging of Pancreatic Adenocarcinoma -- The Role of PET Scanning in Pancreatic Cancer -- Endoscopic Ultrasound Staging -- Laparoscopic Staging -- Surgery for Pancreatic Cancer -- Pancreaticoduodenectomy: Past and Present -- Total Pancreatectomy for Treatment of Pancreatic Adenocarcinoma -- Distal Pancreatectomy -- Vascular Resection for Pancreatic Cancer -- Complications of Pancreaticoduodenectomy -- Controversies in the Surgical Management of Pancreatic Cancer -- Laparoscopic Pancreatic Resections -- Surgical Management of IPMN -- Palliation of Pancreatic Cancer -- Cancer Pain and Symptom Management: Drug Therapy -- Supportive Care: Cachexia, Anorexia Syndrome -- Endoscopic Palliation -- Multimodality Therapy of Pancreatic Cancer -- State of the Art in Radiation Therapy for Pancreas Cancer -- The Evolution of Chemoradiation Strategies for Locally Advanced Pancreatic Cancer -- Optimum Cytotoxic Therapy for Advanced Pancreatic Cancer -- Adjuvant Chemoradiation for Pancreatic Cancer: Past, Present and Future -- Neoadjuvant Treatment for Resectable and Locally Advanced Pancreatic Cancer -- Emerging Targeted Therapies -- An Overview of Clinical Trials of Targeted Therapies in Pancreatic Cancer -- Utility of Animal Models in Pancreatic Cancer Research -- K-ras Inhibitors and Pancreatic Cancer -- HER Family of Receptors as Treatment Targets in Pancreatic Cancer -- GSK-3? Inhibition in Pancreatic Cancer -- Inactivation of NF-?B -- Novel Targets for the Treatment of Pancreatic Cancer I: Insulin-like Growth Factor Receptor -- Novel Targets for the Treatment of Pancreatic Cancer II: The Hedgehog Signaling Pathway -- Development of Vaccine Therapy for Pancreas Cancer -- Novel Approaches in Chemoradiation for Localized Pancreas Cancer -- Incorporation of Genomics and Proteomics in Drug and Biomarker Development -- Pitfalls in Clinical Trials and Future Directions.

Since the first M. D. Anderson Solid Tumor Oncology Series volume on pancreatic cancer, there have been major advances in our understanding of molecular events which underlie pancreatic cancer development, both in the sporadic and inherited forms. We have seen the development of the first mouse models that accurately recapitulate features of the human disease. Several landmark clinical trials in both resectable and metastatic pancreatic cancer have been completed, raising new questions about the standard of care in this disease. Finally, the era of targeted biologic therapies has engendered new excitement about the prospects of more rapid progress in understanding and successfully treating this dreadful disease. Therefore, it is an appropriate time to review these important advances and outline areas of controversy and question in pancreatic cancer biology and treatment.